EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Spatially Directed Microneedle Patch Enables Intratumoral Co‐Delivery of FOLFIRINOX, Surufatinib, and Anti‐PD‐1 for Chemo‐Immunotherapy of Pancreatic Ductal Adenocarcinoma

Tingting Kong, Ximo Xu iD, Xiao Zhang, Chuntao Wu, Zhengjun Qiu, Beiyuan Hu, Zihao Qi, Qiang Tian, Yuqin Yang, Hanguang Dong, Fei Wu, Tuo Jin und 2 weitere

Advanced Science · 2026

DOI: 10.1002/advs.76478 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Tingting Kong und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pancreatic Surgery, Shanghai Key Laboratory of Pancreatic Disease, Shanghai General Hospital, Shanghai Jiao Tong University School of M…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms, Immunotherapy. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, Shanghai Sailing Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC), a lethal malignancy with a 5‐year survival of 13%, faces limited therapeutic efficacy due to fibrotic barriers that block drug access to the therapeutic site, systemic toxicity of conventional chemotherapy, and an immunosuppressive tumor microenvironment (TME). Therapeutic agents with different functions, including FOLFIRINOX (FFX), surufatinib (SUR), and anti‐PD‐1 (αPD‐1), are co‐administered to tumors in animal models using microneedle (MN) patches to achieve site‐targeted synergistic efficacy. The core–shell MN structure is used, with the outer layer providing rapid FFX delivery and the inner layer providing sustained release of SUR and αPD‐1. Compared with intratumoral drug injection and traditional systemic administration, MN patch‐mediated administration markedly suppresses tumor growth and liver metastasis at lower doses, reduces systemic drug exposure and toxicity, and prolongs intratumoral drug retention. In addition, the MN patch‐mediated intratumoral co‐delivery reshapes the TME by boosting CD8 + T cells infiltration, inhibiting Foxp3 + regulatory T cells, and reducing CD206 + tumor‐associated macrophages infiltration, resulting in downregulation of tumor epithelial‐mesenchymal transition and increased tumor cell apoptosis. In summary, MN patch‐mediated delivery of therapeutic agents provides sufficient intratumoral doses and minimizes systemic toxicity through multiple microchannels, suggesting that MN patch co‐delivery is a promising adjunct for enhancing efficacy against PDAC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, Pancreatic DuctalPancreatic NeoplasmsImmunotherapyImmune Checkpoint InhibitorsAnimalsMicroneedle Drug DeliveryHumansMiceIrinotecanOxaliplatinLeucovorinFluorouracilFemaleTumor MicroenvironmentProgrammed Cell Death 1 Receptor

Stichwörter der Autor:innen

chemo‐immunotherapy strategylocalized drug deliverymicroneedlepancreatic ductal adenocarcinomatumor microenvironment

Substanzen

folfirinoxIrinotecanOxaliplatinLeucovorinFluorouracilProgrammed Cell Death 1 ReceptorImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Pancreatic Surgery, Shanghai Key Laboratory of Pancreatic Disease, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Gastroenterology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Laboratory Animal Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine…
  • School of Pharmacy, Shanghai Jiao Tong University, Shanghai, China.

ORCID-Profile: Ximo Xu, Yan Zheng

Förderung

  • National Natural Science Foundation of China
  • National Key Research and Development Program of China
  • Shanghai Sailing Program

Zitieren

APA

Kong, T., Xu, X., Zhang, X., Wu, C., Qiu, Z., Hu, B., Qi, Z., Tian, Q., Yang, Y., Dong, H., Wu, F., Jin, T., Zheng, Y., & Long, J. (2026). A Spatially Directed Microneedle Patch Enables Intratumoral Co‐Delivery of FOLFIRINOX, Surufatinib, and Anti‐PD‐1 for Chemo‐Immunotherapy of Pancreatic Ductal Adenocarcinoma. Advanced Science. https://doi.org/10.1002/advs.76478

Vancouver

Kong T, Xu X, Zhang X, Wu C, Qiu Z, Hu B, et al. A Spatially Directed Microneedle Patch Enables Intratumoral Co‐Delivery of FOLFIRINOX, Surufatinib, and Anti‐PD‐1 for Chemo‐Immunotherapy of Pancreatic Ductal Adenocarcinoma. Advanced Science. 2026. doi:10.1002/advs.76478

BibTeX
@article{Kong2026,
  author = {Kong, Tingting and Xu, Ximo and Zhang, Xiao and Wu, Chuntao and Qiu, Zhengjun and Hu, Beiyuan and Qi, Zihao and Tian, Qiang and Yang, Yuqin and Dong, Hanguang and Wu, Fei and Jin, Tuo and Zheng, Yan and Long, Jiang},
  title = {A Spatially Directed Microneedle Patch Enables Intratumoral Co‐Delivery of FOLFIRINOX, Surufatinib, and Anti‐PD‐1 for Chemo‐Immunotherapy of Pancreatic Ductal Adenocarcinoma},
  journal = {Advanced Science},
  year = {2026},
  doi = {10.1002/advs.76478}
}
Kostenlos starten →